ABT-737

Catalog No.S1002

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Cited by 205 Publications

Cell, 2018, 175(2):429-441

PubMed: 30245008 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):435-449

PubMed: 29533784 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Methods, 2017, 14(9):891-896

PubMed: 28737741 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2013, 19(11):1478-88

PubMed: 24141421 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5770

PubMed: 31852899 ( click the link to review the publication )

EMBO J, 2019, 38(11)

PubMed: 30979778 ( click the link to review the publication )

Dev Cell, 2019, 51(2):277-291

PubMed: 31564612 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2339-2351

PubMed: 30862722 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3657-3671

PubMed: 31216482 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31540244 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31810230 ( click the link to review the publication )

J Cancer, 2019, 10(6):1466-1478

PubMed: 31031856 ( click the link to review the publication )

Thromb Haemost, 2019, 19(10):1665-1674

PubMed: 31493778 ( click the link to review the publication )

Eur J Immunol, 2019, 10.1002/eji.201948254

PubMed: 31411729 ( click the link to review the publication )

Phytomedicine, 2019, 64:153068

PubMed: 31419729 ( click the link to review the publication )

Phytomedicine, 2019, 52:147-156

PubMed: 30599894 ( click the link to review the publication )

Chem Biol Interact, 2019, 309:108723

PubMed: 31228469 ( click the link to review the publication )

J Bone Oncol, 2019, 19:100268

PubMed: 31832331 ( click the link to review the publication )
J Bone Oncol, 2019, 15:100222

PubMed: 30766792 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:897-906

PubMed: 30774376 ( click the link to review the publication )

Platelets, 2019, 30(1):75-80

PubMed: 29125379 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5435

PubMed: 30575733 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(21):5458-5470

PubMed: 30021909 ( click the link to review the publication )

Oncogene, 2018, 37(39):5325-5339

PubMed: 29858601 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):994

PubMed: 30250198 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):199

PubMed: 29415991 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(3):522-531

PubMed: 29278689 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(6):935-946

PubMed: 29545477 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(6):465-474

PubMed: 29394130 ( click the link to review the publication )

Phytother Res, 2018, 32(6):1126-1134

PubMed: 29464855 ( click the link to review the publication )

Thromb Res, 2018, 171:22-30

PubMed: 30240944 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Oncotarget, 2018, 9(42):26834-26851

PubMed: 29928488 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )
J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 29148970 ( click the link to review the publication )

Oncogene, 2017, 36(15):2066-2073

PubMed: 27694901 ( click the link to review the publication )

Cancer Lett, 2017, 411:19-26

PubMed: 28987383 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Biochem Pharmacol, 2017, 140:41-52

PubMed: 28595877 ( click the link to review the publication )

Analyst, 2017, 142(23):4399-4404

PubMed: 29116264 ( click the link to review the publication )

Toxicol In Vitro, 2017, 42:38-46

PubMed: 28366708 ( click the link to review the publication )

Mol Cell Biochem, 2017, 429(1-2):91-102

PubMed: 28120212 ( click the link to review the publication )

Arch Oral Biol, 2017, 73:1-6

PubMed: 27632413 ( click the link to review the publication )

Oncol Lett, 2017, 14(1):903-908

PubMed: 28693250 ( click the link to review the publication )

Asia Pac J Clin Oncol, 2017, 13(2):e144-e152

PubMed: 26552712 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Thromb Haemost, 2017, 117(2):311-324

PubMed: 27929199 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):181-94

PubMed: 26619119 ( click the link to review the publication )

Nat Commun, 2016, 7:11190

PubMed: 27048913 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(5):1138-49

PubMed: 26467384 ( click the link to review the publication )

Br J Pharmacol, 2016, 173(3):471-83

PubMed: 26493374 ( click the link to review the publication )

Br J Cancer, 2016, 114(11):1219-26

PubMed: 27140314 ( click the link to review the publication )

Oncogenesis, 2016, 10.1038/oncsis.2016.33

PubMed: 27159675 ( click the link to review the publication )
J Virol, 2016, 90(5):2356-71

PubMed: 26676786 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(4):562-71

PubMed: 26704388 ( click the link to review the publication )

Lab Invest, 2016, 96(10):1128-37

PubMed: 27617402 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(6):1345-57

PubMed: 27429848 ( click the link to review the publication )

Cancer Cell Int, 2016, 16:27

PubMed: 27042160 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 477(4):607-13

PubMed: 27343560 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):143-148

PubMed: 27449608 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Exp Ther Med, 2016, 11(2):669-673

PubMed: 26893664 ( click the link to review the publication )

Sci Rep, 2016, 6:21264

PubMed: 26887909 ( click the link to review the publication )

Oncotarget, 2016, 7(3):3520-32

PubMed: 26657288 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Oncotarget, 2016, 7(51):85492-85501

PubMed: 27863431 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77815-77824

PubMed: 27780925 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Autophagy, 2015, 11(3):452-9

PubMed: 25715028 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(17):3995-4003

PubMed: 26015514 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.8

PubMed: 25698446 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(19):12290-9

PubMed: 25829495 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:34

PubMed: 25852302 ( click the link to review the publication )

Neurogastroenterol Motil, 2015, 10.1111/nmo.12521

PubMed: 25690069 ( click the link to review the publication )
Int J Oncol, 2015, 46(2):667-76

PubMed: 25434832 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: 25596561 ( click the link to review the publication )

Exp Cell Res, 2015, 335(1):62-7

PubMed: 26024774 ( click the link to review the publication )

Exp Cell Res, 2015, 10.1016/j.yexcr.2015.04.016

PubMed: 25936772 ( click the link to review the publication )

BMC Cancer, 2015, 15:919

PubMed: 26585594 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143685

PubMed: 26606677 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 464(1):286-91

PubMed: 26116776 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 10.1016/j.mrfmmm.2015.04.005

PubMed: ( click the link to review the publication )

Anticancer Res, 2015, 35(3):1803-8

PubMed: 25750346 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36338-53

PubMed: 26462148 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Oncotarget, 2015, 6(1):409-26

PubMed: 25565667 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Nat Commun, 2014, 5:5637

PubMed: 25472497 ( click the link to review the publication )

Autophagy, 2014, 10(10):1776-86

PubMed: 25126729 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5446-55

PubMed: 25208882 ( click the link to review the publication )

Leukemia, 2014, 28(10):1960-8

PubMed: 24577530 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Biomaterials, 2014, 16(2):R41

PubMed: 24745479 ( click the link to review the publication )

Cell Death Differ, 2014, 21(7):1170-7

PubMed: 24682005 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.158

PubMed: 25301069 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.09.024

PubMed: 25304383 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )
Biomaterials Science, 2014, 10.1039/C4BM00072B

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1275

PubMed: 24901046 ( click the link to review the publication )

Acta Neuropathol Commun, 2014, 10.1186/2051-5960-2-57

PubMed: 24887326 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-13-0998

PubMed: 24739394 ( click the link to review the publication )

Mol Cancer Res, 2014, 13(12):3332-42

PubMed: 25154561 ( click the link to review the publication )

Mol Cancer Res, 2014, (4):550-9

PubMed: 24469836 ( click the link to review the publication )

J Immunol, 2014, 193(10):4914-23

PubMed: 25288570 ( click the link to review the publication )

Bone, 2014, 67:166-74

PubMed: 25016096 ( click the link to review the publication )

J Biol Chem, 2014, 289(22):15495-15506

PubMed: 24739390 ( click the link to review the publication )

J Immunother, 2014, 37(1):8-15

PubMed: 24316551 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(11):20500-17

PubMed: 25387078 ( click the link to review the publication )

Int J Hyperthermia, 2014, 30(7):502-12

PubMed: 25354679 ( click the link to review the publication )

Cell Cycle, 2014, 10.4161/15384101.2014.973321

PubMed: ( click the link to review the publication )

Thromb Res, 2014, 134(6):1311-5

PubMed: 25288466 ( click the link to review the publication )

Thromb Res, 2014, 133(1):73-9

PubMed: 24268298 ( click the link to review the publication )

PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84388

PubMed: 24427286 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105049

PubMed: 25126950 ( click the link to review the publication )

PLoS One, 2014, 9(3):e91782

PubMed: 24626299 ( click the link to review the publication )

PLoS One, 2014, 9(5):e96733

PubMed: 24824755 ( click the link to review the publication )
Leuk Lymphoma, 2014, 5:1-12

PubMed: 25373508 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:306718

PubMed: ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

J Neurosci, 2013, 33(46):18098-108

PubMed: 24227720 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e702

PubMed: 23828565 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e762

PubMed: 23928701 ( click the link to review the publication )

Br J Cancer, 2013, 108(9):1870-8

PubMed: 23558901 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e690

PubMed: 23807219 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e801

PubMed: 24030153 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Br J Haematol, 2013, 163(3):377-84

PubMed: 24033315 ( click the link to review the publication )

Br J Haematol, 2013, 161(2):245-54

PubMed: 23398569 ( click the link to review the publication )

Stem Cells Transl Med, 2013, 2(9):690-702

PubMed: 23934910 ( click the link to review the publication )

Cancer Sci, 2013, 104(6):732-9

PubMed: 23421409 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(2):109-21

PubMed: 23233484 ( click the link to review the publication )

Cancer Gene Ther, 2013, 20(7):386-93

PubMed: 23788110 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):6826-34

PubMed: 23329846 ( click the link to review the publication )

Apoptosis, 2013, 18(11):1403-15

PubMed: 23760752 ( click the link to review the publication )

Biomed Pharmacother, 2013, 67(7):583-91

PubMed: 23706691 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 274(2):319-27

PubMed: 24321340 ( click the link to review the publication )

Int J Biochem Cell Biol, 2013, 45(5):944-51

PubMed: 23395630 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78570

PubMed: 24223823 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 437(4):565-72

PubMed: 23850692 ( click the link to review the publication )

Leuk Lymphoma, 2013, 54(2):372-80

PubMed: 22830613 ( click the link to review the publication )
Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2013, 113(3):145-51

PubMed: 23557083 ( click the link to review the publication )

J Ovarian Res, 2013, 6(1):72

PubMed: 24103422 ( click the link to review the publication )

Cytometry A, 2013, 83(2):227-34

PubMed: 23165976 ( click the link to review the publication )

Blood, 2012, 120(19):3978-85

PubMed: 22927247 ( click the link to review the publication )

Mol Cell, 2012, 46(5):573-83

PubMed: 22560721 ( click the link to review the publication )

J Clin Invest, 2012, 122(6):2018-31

PubMed: 22622039 ( click the link to review the publication )

EMBO J, 2012, 31(10):2322-35

PubMed: 22510886 ( click the link to review the publication )

Oncogene, 2012, 31(26):3177-89

PubMed: 22056880 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(3):R96

PubMed: 22703841 ( click the link to review the publication )

Anal Chem, 2012, 84(11):4703-10

PubMed: 22533353 ( click the link to review the publication )

Br J Haematol, 2012, 159(5):565-71

PubMed: 23025479 ( click the link to review the publication )

Mol Cancer Res, 2012, 10(3):347-59

PubMed: 22241218 ( click the link to review the publication )

J Biol Chem, 2012, 287(25):21357-70

PubMed: 22553204 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17682-92

PubMed: 22433870 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(9):1508-20

PubMed: 22771494 ( click the link to review the publication )

Phytother Res, 2012, 27(6):835-40

PubMed: 22899281 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

PLoS One, 2012, 7(8):e43158

PubMed: 22912816 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52333

PubMed: 23284992 ( click the link to review the publication )

J Pharmacol Sci, 2012, 119(4):330-40

PubMed: 22814102 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

J Clin Invest, 2011, 121(3):1053-63

PubMed: 21317538 ( click the link to review the publication )

Leukemia, 2011, 25(11):1728-38

PubMed: 21701487 ( click the link to review the publication )
Neuro Oncol, 2011, 13(12):1265-76

PubMed: 21880625 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

Oncogene, 2011, 30(37):3918-29

PubMed: 21460857 ( click the link to review the publication )

Am J Nephrol, 2011, 34(6):549-59

PubMed: 22123611 ( click the link to review the publication )

Cancer Chemoth Pharm, 2011, 67(3):557-67

PubMed: 20473610 ( click the link to review the publication )

PLoS One, 2011, 6(6):e20423

PubMed: 21674052 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24102

PubMed: 21949692 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Curr Pharmacogenomics Person Med, 2011, 9(3):184-190

PubMed: 22162984 ( click the link to review the publication )

Mol Cancer Ther, 2010, 19(20):5591-601

PubMed: 20587662 ( click the link to review the publication )

J Biol Chem, 2010, 285(26):19910-20

PubMed: 20421300 ( click the link to review the publication )

Apoptosis, 2010, 15(10):1256-69

PubMed: 20582477 ( click the link to review the publication )

Exp Hematol, 2010, 38(10):908-921

PubMed: 20540984 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Features

First-generation inhibitor of anti-apoptotic Bcl-2 proteins.

Targets

Bcl-2 ^[1] (Cell-free assay)	Bcl-xL ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)	Bcl-B ^[1] (Cell-free assay)
30.3 nM(EC50)	78.7 nM(EC50)	197.8 nM(EC50)	1.82 μM(EC50)

In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. ^[1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. ^[2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. ^[3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. ^[4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
OCI-Ly1	M3[zfWNmdGxiVnnhZoltcXS7IFHzd4F6	NUnVfoF[OjVyIH7NxsA>	MUC3NkBp	NY\GXWVsTE2VTx?=	Mke3Z4F2e2WmIEm3KUBtd3O\|IH;mJJZq[WKrbHn0fUBqdiClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJGJEVDZic3nSUmE>	M2LLTlI3PjV5Mki4
KG1a	M2P5WGNmdGxiVnnhZoltcXS7IFHzd4F6	MkfyNE0yOCEQvF2=	NU\XeFBSOjRiaB?=	MmLxSG1UVw>?	NGPMc4hKSzVyPUeuOlgh\|ryPLDDk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M4G3[\|I3PTV{N{Gy
Kasumi-1	MlrUR4VtdCCYaXHibYxqfHliQYPzZZk>	M4nGRVAuOTBizszN	NWHsWllNOjRiaB?=	MoXmSG1UVw>?	M2LEVGlEPTB;ND64O{DPxE1uIHTlZ5Jm[XOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NHu3doYzPjV3MkexNi=>
KG1a	MYTBdI9xfG:\|aYOgRZN{[Xl?	MYWwMVExKM7:TR?=	NGL5b3IzPCCq	Mlq2SG1UVw>?	MX\pcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MVKyOlU2OjdzMh?=
Kasumi-1	NEHGVZJCeG:ydH;zbZMhSXO\|YYm=	MnTsNE0yOCEQvF2=	MnnCNlQhcA>?	MlvISG1UVw>?	NFfoSJFqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MkixNlY2PTJ5MUK=
MC-3	NH\QelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmSxOU8yOC9{MDFOwG0>	MYSyOEBp	MoC5SG1UVw>?	M4S4[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MVWyOlQ1PzZzNR?=
HN22	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGS2cWkzNjVxNz61M\|IzNjVizszN	NYKxNoJ1OjRiaB?=	M2DwbGROW09?	MkHIbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NGjKSo0zPjR2N{[xOS=>
MC-3	NYjGeIpWSXCxcITvd4l{KEG\|c3H5	Mn3DOU8yOC9{MDFOwG0>	MYmyOEBp	NUi2To1zTE2VTx?=	NHLjcINqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz	MV[yOlQ1PzZzNR?=
HN22	MlnDRZBweHSxc3nzJGF{e2G7	NVX4WXBYOi53L{euOU8zOi53IN88US=>	MY[yOEBp	NHLjWmFFVVOR	NV\rdItUcW6mdXPld{Bk[XOyYYPlMY1m\GmjdHXkJIFxd3C2b4Ppdy=>	NUK0boZ7OjZ2NEe2NVU>
MOLT-4	MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVyxNE02ODByIH7N	M2XzelczKGh?	MoXISG1UVw>?	NUHQfVV4UUN3ME2wMlE6QCEQvF2=	NGrN[\|MzPjN7MkOzNi=>
RS4;11	M4XVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDRNVAuPTByMDDuUS=>	NGHIOJY4OiCq	NV:zdHZ5TE2VTx?=	Mmi3TWM2OD1yLkCwNkDPxE1?	MV[yOlM6OjN\|Mh?=
JURKAT	NYX5cZhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTMNVAuPTByMDDuUS=>	MYS3NkBp	NEDkcYpFVVOR	MlHLTWM2OD14NjFOwG0>	NF\JT2ozPjN7MkOzNi=>
CEM R	NV\CPWFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHjfWoyOC13MECwJI5O	MYW3NkBp	M2HSb2ROW09?	MXjJR\|UxRTVwNDFOwG0>	Mo\vNlY{QTJ\|M{K=
CEM S	NV2zOFFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LsUlExNTVyMECgcm0>	MlnQO\|IhcA>?	NHW0SHJFVVOR	NIrmZ5JKSzVyPUGyMlEh\|ryP	MUmyOlM6OjN\|Mh?=
MOLT-4	NFSxcIRCeG:ydH;zbZMhSXO\|YYm=	MWSxNE0yODByIH7N	M17kNVI1KGh?	NVu5UJc1TE2VTx?=	MnfGZ4F2e2W\|IITo[UBkdGWjdnHn[UBw\iCEY3ytNkBidmRidHjlJIRwf26{ZXf1cIF1cW:wIH;mJGJkdC26TDDhcoQhVWOuLUG=	NGrBeZYzPjN7MkOzNi=>
CEM S	NV7ObGJUSXCxcITvd4l{KEG\|c3H5	M2jJU\|ExNTFyMECgcm0>	NXnLN5lKOjRiaB?=	M{PLdWROW09?	M1\tWYNifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x	M2HkOVI3Ozl{M{Oy
JURKAT	M3PyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYCxNFAuOTByMDDuUS=>	NVrYXZp6PDhiaB?=	MXvEUXNQ	NVfJWVlKUUN3ME25OVXDuTlwMzDuUS=>	NEDmVWIzPjF5MkK2PS=>
LOUCY	Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2W4OFExOC1zMECwJI5O	NI\qOVE1QCCq	MkK3SG1UVw>?	MUnJR\|UxRTN{LklCtVExNjlibl2=	NGrHTYQzPjF5MkK2PS=>
WM-115	NVv3bVNLS2WubDDWbYFjcWyrdImgRZN{[Xl?	NVnMO41UOTBywrDuUS=>	MlnjO\|IhcA>?		MkPU[Y5p[W6lZYOgZ5Vz[3WvaX6tbY5lfWOnZDDhcpRqNXO3co\peoFtyqB?	MoXnNlYyOTZ5N{[=
B16	M1XieWNmdGxiVnnhZoltcXS7IFHzd4F6	NIHqZ3UyODEEoH7N	NVjwSWR[PzJiaB?=		MULlcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>?	MXmyOlEyPjd5Nh?=
HL-60	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYq3NkBp		MW\JR\|UxyqB;IEGwMlchdk1?	M1zjTFI3ODR3NkC5
MOLM-13	NHfCeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUW3NkBp		M3faN2lEPTEEoE2gNlcvQSCwTR?=	M3:0VVI3ODR3NkC5
OCI-AML3	MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIrCcZk4OiCq		MoTyTWM2OMLiPTCxPVUxKG6P	MV:yOlA1PTZyOR?=
BCWM.1	M3PmSGFxd3C2b4Ppd{BCe3OjeR?=	MmnYNE0yNjZizszN	MYOyOEBp		M{fpNYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	M3[xSVI2QDl\|Mkmw
MWCL-1	MoexRZBweHSxc3nzJGF{e2G7	M1LZWVAuOS54IN88US=>	NGT3S4MzPCCq		M1i2c4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	M{L2NFI2QDl\|Mkmw
MM.1s	M{DEVGFxd3C2b4Ppd{BCe3OjeR?=	MmGzNE0yNjZizszN	NGfaPYozPCCq		M2fs[4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	M{jheVI2QDl\|Mkmw
HCT116	M1;B[mZ2dmO2aX;uJGF{e2G7	MWGzM\|ExKM7:TR?=	NVvXVXlWOTMEoHlCpC=>	NEjVNmFFVVOR	M{\5O4lv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG\|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?=	MmXKNlU4OTVyMki=
HCT116 BAX BAK1 DKO	NUf6UGZKTnWwY4Tpc44hSXO\|YYm=	MnTyN{8yOCEQvF2=	MmfLNVLDqGkEoB?=	M3u5cmROW09?	NW\mTVNycW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKEyFM1KtTWkh[2:wdnXyd4lwdiCjbnSgV3FUXE1zIHTl[5Ji\GG2aX;u	NVr6V2ZOOjV5MUWwNlg>
HCT116	MVXGeY5kfGmxbjDBd5NigQ>?	NVW4dlh4OTBizszN	MYSxNuKhcMLi	Ml6zSG1UVw>?	NGfPV4NqdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th	MV:yOVcyPTB{OB?=
HCT116 BAX BAK1 DKO	NYC1UFdyTnWwY4Tpc44hSXO\|YYm=	NFvtUowyOCEQvF2=	MnTQNVLDqGkEoB?=	MkLhSG1UVw>?	MX;pcoNz\WG\|ZYOgS2ZRNUyFM1KgdJVv[3Sj	NYPZU5FzOjV5MUWwNlg>
HCT116	NYX4XnFNSXW2b4DoZYd6KEG\|c3H5	NGDr[YsyOCEQvF2=	MYmxNuKhcMLi	M3XwR2ROW09?	Mn\MbY5lfWOnczDhJINwdXCuZYTlJIF2fG:yaHHnbYMhemW\|cH;ud4U>	MknONlU4OTVyMki=
HCT116 BAX BAK1 DKO	MV;BeZRweGijZ4mgRZN{[Xl?	NIfiU2MyOCEQvF2=	NGTYSIcyOsLiaNMg	M{WxOWROW09?	NUWwcGdycW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNicnXzdI9ve2V?	MV2yOVcyPTB{OB?=
U937	Mn;1RZBweHSxc3nzJGF{e2G7	NI\oZ2QxNjF{NT2yJO69VQ>?	NHrsdnMzPCCq		MX3lcohidmOnczDETGEwYC1zMT3pcoR2[2WmIHHwc5B1d3Orcx?=	NF7GNFEzPTdzNECyOC=>
U937	MkjoRZBweHSxc3nzJGF{e2G7	M1zYSVAvPSEQvF2=	MXqyOEBp		M2XzUYVvcGGwY3XzJINt\WG4YXflJI9nKFCDUmCgZY5lKGOjc4Dhd4UuOyCjczD3[YxtKGG\|IF7vfIEhdGW4ZXy=	MnLONlU4OTRyMkS=
HL-60 AAA-Bcl-2	MWTBdI9xfG:\|aYOgRZN{[Xl?	MVOwMVUh\|ryP	Mm\0OFghcA>?		NH7kOnRKSzVyPUCuPFch\|ryv78{MbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MXeyOVcyOTR4MB?=
HL-60 EEE-Bcl-2	NYHXV5dySXCxcITvd4l{KEG\|c3H5	MVmwMVUh\|ryP	M4XTOlQ5KGh?		M{C0U2lEPTB;NTFOwI3wxIxiaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M3jaVlI2PzFzNE[w
U87	M2iyUGZ2dmO2aX;uJGF{e2G7	NGH0OIE2OCEQvF2=	MUeyOEBp		NV;2UZdtemWmdXPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsd{Bw\iCPTWCtNkwhVU2SLUG0JIFv\CCEY3ytNi=>	NYLjb\|F2OjV4Nke2OlM>
K562	NXn2PIZKS2WubDDWbYFjcWyrdImgRZN{[Xl?	NVrGTWRqOS1zMDFOwG0>	NGG0XIw1QCCq	MoHkSG1UVw>?	M2faU2lEPTB;Mk[uO{DPxE1?	NXfLVZJHOjV3OU[1OlE>
K562/Mcl -1-IRESBim	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTlwMzFOwG0>	MoHuNlU2OzV7MEC=
K562/Bcl- 2-IRESBim	NHSzU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDoTWM2OD1yLkO1JO69VQ>?	NUfMOHRCOjV3M{W5NFA>
Jurkat	NIrYN\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nvXGlEPTB;MD62OkDPxE1?	MkLINlU2OzV7MEC=
JurkatΔBak	M3PwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfzOmxKSzVyPkWwJO69VQ>?	NUnOVm84OjV3M{W5NFA>
HL60/VCR	MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRjFyMDFOwG0>	M2jBN\|I2PTN3OUCw
Kasumi-1	NI\VOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPUXINWUUN3ME2wMlAyKM7:TR?=	MUiyOVU{PTlyMB?=
Kasumi-1/ABT	M{PTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DTSmlEPTB;MD61NUDPxE1?	Mn3XNlU2OzV7MEC=
THP-1	NUDxfY9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTFwMkeg{txO	NVHMR\|NtOjV3M{W5NFA>
U937	NHvaZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTVwMkmg{txO	M{P2[lI2PTN3OUCw
C1498	NFLXR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIq4eYtKSzVyPU[uNVMh\|ryP	NILSfYczPTV\|NUmwNC=>
RPMI 8226	MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVWxNWZoUUN3ME2wMlI2KM7:TR?=	NIPSN3kzPTV\|NUmwNC=>
MM.1S	Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTBwNECg{txO	NYHJXG9ROjV3M{W5NFA>
NCI-H929	MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PVbGlEPTB;MUWuNlEh\|ryP	NIH0eFUzPTV\|NUmwNC=>
U266	M{HnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;vRlRnUUN3ME2wMlY5KM7:TR?=	NYXNeFFrOjV3M{W5NFA>
MCF-7	MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NWrJSFFHPSEQvF2=	MV60PEBp	M1Xmb2ROW09?	NWHyepV5\W6qYX7j[ZMhfGinIIPlcpNqfGm4aYT5JJRwKG:{IILh[IlifGmxbh?=	MnztNlU1ODlzMkS=
MCF-7	MoTURZBweHSxc3nzJGF{e2G7	MY[1JO69VQ>?	NGHNO3Y1NzJ2L{S4JIg>	MojuSG1UVw>?	NXntVZRJcW6lcnXhd4V{KHSqZTDjcIVifmWmIGDBVnA>	M1fUWFI2PDB7MUK0
MCF-7	NVzBSmVWTnWwY4Tpc44hSXO\|YYm=	M{nodFUh\|ryP	NGm2ZWkzPCCq	NVi0UWNlTE2VTx?=	MlHh[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW\|c3nvcuKh	M2nC[lI2PDB7MUK0
MDA-MB 231	M3HobmZ2dmO2aX;uJGF{e2G7	M1v2VVUh\|ryP	NEKzUZAzPCCq	NHnNNmhFVVOR	NGXyRYxmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB?	Mnr2NlU1ODlzMkS=
ZR-75-1	NYfa[np2TnWwY4Tpc44hSXO\|YYm=	NHq1cIc2KM7:TR?=	MnPONlQhcA>?	M{jkcmROW09?	MnH2[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW\|c3nvcuKh	NIO5[IszPTRyOUGyOC=>
A549	M1G5[WNmdGxiVnnhZoltcXS7IFHzd4F6	MXuwMVIxKM7:TR?=	M{PCZ\|czKGh?	NH;WdWhFVVOR	MlH4[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	M1vF[VI2Ozh6N{[y
H1299	NGezTmxE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M2Lo[FAuOjBizszN	MXi3NkBp	NUHhclZKTE2VTx?=	NEDFZ5Nl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw	NIqzTWQzPTN6OEe2Ni=>
HO-8910	MmSyR4VtdCCYaXHibYxqfHliQYPzZZk>	NIPpSHUxNTJyIN88US=>	M4\hRVczKGh?	M{LGe2ROW09?	NE[4Zoll\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw	MVOyOVM5QDd4Mh?=
HT-29	NHXFV2lE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NEDrZWsxNTJyIN88US=>	Mnn4O\|IhcA>?	NX34WmRwTE2VTx?=	M13nXIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5?	NVjOc2pQOjV\|OEi3OlI>
HCT-116	Mm\lR4VtdCCYaXHibYxqfHliQYPzZZk>	M4jneVAuOjBizszN	MVS3NkBp	MnHjSG1UVw>?	NGL4bmhl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw	M4\3UFI2Ozh6N{[y
A549	NYTEXFRsSXCxcITvd4l{KEG\|c3H5	MYKyNEDPxE1?	NVTzc5pYPDhiaB?=	MVTEUXNQ	Mmi0bY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6=	MWCyOVM5QDd4Mh?=
H1299	M4HMNWFxd3C2b4Ppd{BCe3OjeR?=	NHKySFYzOCEQvF2=	MkTsOFghcA>?	MUnEUXNQ	NGPyPFJqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XOyaYLpci=>	NFvCeWEzPTN6OEe2Ni=>
Sc-1	M1S2N2NmdGxiVnnhZoltcXS7IFHzd4F6	NEnLfWkxNjByMEGtNUDPxE1?	MoLSPVYhcA>?		Mlqw[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NVzvd3hXOjV\|N{O1NFg>
OcI-LY18	MoDHR4VtdCCYaXHibYxqfHliQYPzZZk>	MVSwMlAxODFvMTFOwG0>	MWi5OkBp		M3PSdIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M3\TZVI2Ozd\|NUC4
RL	MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M1LOSlAvODByMT2xJO69VQ>?	MoLlPVYhcA>?		MV;k[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NX7oeYlYOjV\|N{O1NFg>
RKO	M3Trc2NmdGxiVnnhZoltcXS7IFHzd4F6	MmDRNE0yOCEQvF2=	NVG0dHB4OjUkgJnoxsA>	M3WwXmROW09?	NGHEflRKSzVyPvMAjVI26oDLwsXN	M162UVI2OzB2M{iz
Caco-2	Mm\hR4VtdCCYaXHibYxqfHliQYPzZZk>	M3\uOFAuOTBizszN	NF\4R3YzPOLCiXlCpC=>	NXvGT4g1TE2VTx?=	NVTGc3UzUUN3ME2xPU446oDLwsXN	MYKyOVMxPDN6Mx?=
DLD1	MnXUR4VtdCCYaXHibYxqfHliQYPzZZk>	MYewMVExKM7:TR?=	MlrBNlTjiImqwrC=	M3LGeWROW09?	NGjuT41KSzVyPUG4Mlc56oDLwsXN	NVH6NplkOjV\|MESzPFM>
LS411N	MnTLR4VtdCCYaXHibYxqfHliQYPzZZk>	M3r4e\|AuOTBizszN	MlraNlTjiImqwrC=	MorPSG1UVw>?	MXjJR\|UxRTFzLkS35qCKyrWP	MYSyOVMxPDN6Mx?=
SW620	MoH6R4VtdCCYaXHibYxqfHliQYPzZZk>	NWO2[ohmOC1zMDFOwG0>	NHLQ[I0zPOLCiXlCpC=>	M3n6R2ROW09?	M{D0eGlEPTB;MUKuNlTjiIoEtV2=	MX:yOVMxPDN6Mx?=
HCT116	MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NGm5bogxNTFyIN88US=>	NIT5[HczPOLCiXlCpC=>	Mk\XSG1UVw>?	MluwTWM2OD1{MD60PgKBkcL3TR?=	M1PQ[FI2OzB2M{iz
HaCaT	NV3RbFNmS2WubDDWbYFjcWyrdImgRZN{[Xl?	NYi3e\|IxOC5zL{GvNVAh\|ryP	M{\qNlI1KGh?	NUT2dJA6TE2VTx?=	MV3k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NWX3R49kOjV{MUC3PVU>
A5-RT3	NWTk[GFUS2WubDDWbYFjcWyrdImgRZN{[Xl?	Ml3aNE4yNzFxMUCg{txO	M4\a[VI1KGh?	M1r1ZWROW09?	NELUdm9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NYXvUWhyOjV{MUC3PVU>
HaCaT	M4HF[GZ2dmO2aX;uJGF{e2G7	MkLBNVDjiIoQvF2=	NGXpNogzPC92ODDo	NInGXVNFVVOR	NX7abmRlcW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u	M1jHOlI2OjFyN{m1
A5-RT3	M{\ZcGZ2dmO2aX;uJGF{e2G7	NY\vZlBXOTEkgJpOwG0>	MYiyOE81QCCq	MWHEUXNQ	NXrsXnU{cW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u	M3;U[FI2OjFyN{m1
A5-RT3	M4nVPWZ2dmO2aX;uJGF{e2G7	M{\yOFUh\|ryP	MnPMOkBp	NWnQe25mTE2VTx?=	MkTzbY5lfWOnczD0bIUhemWuZXHz[UBw\iCvaYTvZ4hwdmS{aXHsJJBzd3SnaX7zJIFv\CC{ZXT1Z4V{KGOub37v[4VvcWNic4Xyeol3[WxiaX6gZUBk[XOyYYPlMYlv\GWyZX7k[Y51KG2jbn7ldi=>	MVWyOVIyODd7NR?=
U266	MoPqSpVv[3Srb36gRZN{[Xl?	MWm1NFAwPzVyIH7N	MUmyOE81QCCq	MojRSG1UVw>?	NGDmSXNld3ewcnXneYxifGW\|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm\|b3\vdo0>	M3LM[VI2OjB6OEi4
RPMI8226	M3zWUWZ2dmO2aX;uJGF{e2G7	MWO1NFAwPzVyIH7N	NWHMNFFOOjRxNEigbC=>	NWi5ZWlETE2VTx?=	M{PUUIRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=>	NHXhVGMzPTJyOEi4PC=>
MM.1S	MYDGeY5kfGmxbjDBd5NigQ>?	MW[1NFAwPzVyIH7N	MVSyOE81QCCq	NFviPHdFVVOR	Ml;o[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt	NEKwOIgzPTJyOEi4PC=>
Clone A	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;ENE4z6oDVNkCg{txO	NV\RNIZpPzJiaB?=	M1PTVmROW09?	Mmi2TWM2OD15LkWg{txO	M2rJW\|I2OjB6OEiy
CX-1	NITpTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ixRVAvOuLCk{[wJO69VQ>?	M33DZ\|czKGh?	NYjYUoVuTE2VTx?=	NULvdHdjUUN3ME2xMlgh\|ryP	MVqyOVIxQDh6Mh?=
LS174T	NF\aOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fnUFAvOuLCk{[wJO69VQ>?	MmP3O\|IhcA>?	M3;5cmROW09?	NXzZ[FBTUUN3ME2xPE4{KM7:TR?=	M{DZcFI2OjB6OEiy
HT29	MlT2RZBweHSxc3nzJGF{e2G7	MkHPNU82NzFyIN88US=>	NITKTJo1QCCq		M{ntc4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	Mk\ZNlUyQTJzOEi=
SW480	NHLpSYJCeG:ydH;zbZMhSXO\|YYm=	M3XXdVEwPS9zMDFOwG0>	MkjzOFghcA>?		NV7KVGh[[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	Mn3LNlUyQTJzOEi=
Colo205	MlTKRZBweHSxc3nzJGF{e2G7	Mle0NU82NzFyIN88US=>	NXK1V\|V7PDhiaB?=		MUXjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NWfVXI85OjVzOUKxPFg>
Caco2	MVTBdI9xfG:\|aYOgRZN{[Xl?	MVOxM\|UwOTBizszN	NVrGUHhLPDhiaB?=		MX3jZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NG\K[24zPTF7MkG4PC=>
PCI-13	NEPD[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWO3NkBp	NHLWV4NFVVOR	NF\4RXRIUTVyPUG1JOKyKDFwODFOwG0>	MYWyOVE{QTN6Nx?=
PCI-15B	MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV[1TmhFPzJiaB?=	NUHxdXZ[TE2VTx?=	Ml;0S2k2OD1zMTFCtUA1NjVizszN	NEHEdokzPTF\|OUO4Oy=>
UM-SCC22B	NV[4PIlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXS3NkBp	MU\EUXNQ	MkfpS2k2OD1zOTFCtUAzNjlizszN	NYr2U3Y{OjVzM{mzPFc>
UM-SCC47	M2rDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml\UO\|IhcA>?	NEDJNFRFVVOR	MVLHTVUxRTF7INMxJFEzNjNizszN	NYW0VIlvOjVzM{mzPFc>
93-VU-147T	NHP1NpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVq3NkBp	M2C3e2ROW09?	M{j1W2dKPTB;ND6zJOKyKDNwNTFOwG0>	M{Wz[lI2OTN7M{i3
UD-SCC2	Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{P6V\|czKGh?	NFzhXnFFVVOR	M2fpd2dKPTB;MkigxtEhOi57IN88US=>	MXGyOVE{QTN6Nx?=
UPCI:SCC90	M2DxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHnIT5g4OiCq	NVLO[ppoTE2VTx?=	NVW0VYd6T0l3ME22MlYhyrFiMT61JO69VQ>?	Mlu5NlUyOzl\|OEe=
RPMI-8226	NVrQPYw5S2WubDDWbYFjcWyrdImgRZN{[Xl?	MVixNlUwOjVyL{WwNEBvVQ>?	MoixOFhpyqB?	M3\oWWROW09?	M3PNbIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MWKyOVAxQDJyMh?=
OPM-2	MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NFX0SIkyOjVxMkWwM\|UxOCCwTR?=	M3jncVQ5cMLi	MXTEUXNQ	M13TXIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NHnWT4EzPTByOEKwNi=>
RPMI-8226	MVjBdI9xfG:\|aYOgRZN{[Xl?	Mn7UNVI2NzJ3MD:1NFAhdk1?	MoXIOFhpyqB?	MnHiSG1UVw>?	NFfvcI9qdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M2fCcFI2ODB6MkCy
OPM-2	MorwRZBweHSxc3nzJGF{e2G7	MUexNlUwOjVyL{WwNEBvVQ>?	MnPoOFhpyqB?	MlPESG1UVw>?	MXfpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NEPldJkzPTByOEKwNi=>
COG-LL-319	M2m4PGZ2dmO2aX;uJGF{e2G7	MnzzNVAxKG6P	NF71WJUyNzNxNjDo	M1\xNGROW09?	NWf5c4l[cW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBO[2xvMTDjcIVifmGpZR?=	MUSyOFk2OTR5Mh?=
RS4;11	NVzNfFc3TnWwY4Tpc44hSXO\|YYm=	MlmwNVAxKG6P	NXH1UpBYOS9\|L{[gbC=>	M2fuRWROW09?	MVnpcoR2[2W\|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm	MYKyOFk2OTR5Mh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PARP / c-PARP / cleaved caspase 3 ; PubMed: 21393866 J Clin Invest H146 cells were preincubated in normoxia or hypoxia (1% O2) for 18 hours prior to treatment with ABT-737 (89.1 nM ), after which cells were harvested for protein analysis by Western blot. Hif-1a; PubMed: 22006676 Mol Cancer Ther Representative western blots for HIF-1α, PARP and cleaved caspase 3 in response to 24-72 hr exposure to ABT-737 in varying concentration in normoxia and hypoxia in 4 neuroblastoma cell lines. Actin is shown as a loading control. Blots are representative of 3 independent experiments. γ-H2AX / p-ATM; PubMed: 21084274 Cancer Res Induction of γ-H2AX and p-ATM by ABT-737. Cells were treated with 10 µmol/L ABT-737 for 24 hours and then maintained in fresh media for 1 or 2 more days prior to Western blot analysis.	21393866 22006676 21084274
Immunofluorescence	cytochrome C; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the release of mitochondrial cytochrome c (green) into the cytoplasm after ABT-737 exposure (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. Bax; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bax from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field C. To assess whether ABT-737 treatment has an effect on the dimerization of Bax, the levels of dimeric Bax were measured with or without ABT-737 treatment in MC-3 and HN22 cells. Bim; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bim from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. AIF; PubMed: 25034785 Cell Death Differ localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification × 60, zoom × 3, bar 20 μm. p65 ; PubMed: 28846096 Nat Cell Biol BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-Oph (30 μM) for 1 h, immunostained for p65 and analysed by confocal microscopy. TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar represents 30μM. Representative images from three independent experiments.	26447615 25034785 28846096
Growth inhibition assay	Cell viability; PubMed: 22311987 J Biol Chem Stably transfected K562 cells were treated with increasing concentrations of ABT-737, obatoclax, or maritoclax for 24 h. Cell viability was determined by measuring intracellular ATP levels with the CellTiter Glo assay.	22311987
ELISA	IL-6 / IL-8; PubMed: 21084274 Cancer Res The secretion of IL-6 and IL-8 in PV-10 cells treated with DMSO, ABT-737 or enantiomer for 24 hours was determined by ELISA.	21084274

In vivo

In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. ^[1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. ^[2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Fluorescence polarization assays: Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research: ^[4]	- Collapse Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114 Concentrations: 0.001-10 μM Incubation Time: 48 hours Method: SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%) Dosages: 20 and 30 mg/kg Administration: For intraperitoneal (i.p.) every day (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (122.93 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% Propylene glycol, 5% Tween 80, 65% D5W For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download ABT-737 SDF

Molecular Weight	813.43
Formula	C₄₂H₄₅ClN₆O₅S₂
CAS No.	852808-04-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommended method about reconstitution of the compound for in vivo animal study?
Answer:
For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

ABT-737

Cited by 205 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download ABT-737 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Choose Your Country or Region

By Signaling Pathways

By product type

ABT-737

Cited by 205 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download ABT-737 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)